These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27687905)

  • 21. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of rivaroxaban in real-life treatment of venous thromboembolism: results of the TEV Survey, an Italian epidemiological study].
    Pesavento R; Iori I;
    G Ital Cardiol (Rome); 2017 Mar; 18(3):239-246. PubMed ID: 28398382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack.
    Chu A; Limberg J
    Am J Emerg Med; 2017 Dec; 35(12):1910-1914. PubMed ID: 28869100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unusual rapid progression of non-bacterial thrombotic endocarditis in a patient with bladder cancer despite undergoing intensification treatment with rivaroxaban for acute venous thromboembolism.
    Fujimoto D; Mochizuki Y; Nakagiri K; Shite J
    Eur Heart J; 2018 Nov; 39(43):3907. PubMed ID: 30203033
    [No Abstract]   [Full Text] [Related]  

  • 27. Rivaroxaban for treatment of venous thromboembolism in older adults.
    Mitchell AP; Conway SE
    Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The EINSTEIN CHOICE study].
    Agnelli G; Becattini C; Giustozzi M; Imberti D; Benedetti R; Fontana M
    G Ital Cardiol (Rome); 2017 Sep; 18(9):613-617. PubMed ID: 28845870
    [No Abstract]   [Full Text] [Related]  

  • 29. Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
    Theodorou JM; Patel Y; Ford P
    J Pharm Pract; 2017 Jun; 30(3):381-384. PubMed ID: 27026636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Camm AJ
    Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
    Yang VK; Cunningham SM; Rush JE; de Laforcade A
    J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):729-36. PubMed ID: 26990131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban Use in Patients with Hemoglobinopathies.
    Apostolou C; Klonizakis P; Mainou M; Kapsali E; Kafantari K; Kotsiafti A; Vetsiou E; Vakalopoulou S; Vlachaki E
    Hemoglobin; 2017 May; 41(3):223-224. PubMed ID: 28950780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism": Comment.
    Lijfering WM
    J Thromb Haemost; 2022 Jul; 20(7):1747. PubMed ID: 35754012
    [No Abstract]   [Full Text] [Related]  

  • 34. "Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism": Reply.
    Bistervels IM; Bavalia R; Middeldorp S; Coppens M
    J Thromb Haemost; 2022 Jul; 20(7):1748-1749. PubMed ID: 35754011
    [No Abstract]   [Full Text] [Related]  

  • 35. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
    Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
    Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
    Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry.
    Speed V; Patel JP; Roberts LN; Patel RK; Arya R;
    Thromb Res; 2021 Jan; 197():16-19. PubMed ID: 33160116
    [No Abstract]   [Full Text] [Related]  

  • 38. Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease.
    Rapista N; Sarkar S; Chaudhary R
    J Thromb Thrombolysis; 2020 Nov; 50(4):982-983. PubMed ID: 32495012
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country.
    Boietti B; Fili S; Peuchot V; Tabares A; Vázquez F; Gándara E
    Thromb Res; 2021 Aug; 204():143-145. PubMed ID: 33593595
    [No Abstract]   [Full Text] [Related]  

  • 40. Spontaneous splenic rupture due to rivaroxaban.
    Nagaraja V; Cranney G; Kushwaha V
    Drug Ther Bull; 2018 Nov; 56(11):136-139. PubMed ID: 30355723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.